Monographie - Ceftazidime Avibactam - Stabilis 4.0

Ultimele actualizari :
19/11/2024

Antibiotic

Ceftazidime Avibactam

Injectabil

Stabilitatea in solutie

Stabilitatea in amestec

Factorii care influenteaza stabilitatea

Compatibilitate

Microunde

Bibliografie

pdf

Formula chimica

Denumirea comerciala

Denumirea comerciala

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Avycaz	SUA
Torgena	Brazilia
Zavicefta	Argentina, Australia, Belgia, Chilli, Elvetia, Finlanda, Franta, Germania, Irlanda, Italia, Luxemburg, Marea Britanie, Mexic, Norvegia, Peru, Romania, Slovenia, Spania, SUA, Suedia, Tunisia, Ungaria

Bibliografie

Injectabil

Bibliografie : Ceftazidime Avibactam

	tip	publicare
2902	Laborator	Ceftazidime - avibactam (Avycaz®) - Summary of Product Characteristics Forrest Pharmaceuticals 2015
3520	Laborator	Cidomycin - Summary of product Chracteristics. Sanofi 2011
3549	Laborator	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3643	Laborator	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Laborator	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3984	ziar	Meyer K, Santarossa M, Danziger L.H, Wenzler E. Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water. Hosp Pharm 2017 ,52;3 : 221-228
4055	ziar	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	ziar	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4434	ziar	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4528	ziar	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4548	ziar	O'Donnell J.N, Xu A, Lodise T.P. Intravenous Compatibility of Ceftazidime/Avibactam and Aztreonam Using Simulated and Actual Y-site Administration. Clin Ther 2020 ; 42, 8: 1580-1586.
4634	ziar	Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics 2022 ;11,4: 458
4801	ziar	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4822	ziar	Naicker S, Roberts J.A, Won H, Wallis S.C, Unwin S, Jamieson C, Hills T, Gilchrist M, Santillo M, Seaton R.A, Drummond F, Sime Evaluation of the stability of ceftazidime/avibactam in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy utilizing a national stability protocol framework. JAC Antimicrob Resist 2024

Mentions Légales